Autologous Pluripotent Stem Cell–Derived β-Like Cells for Diabetes Cellular Therapy
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Development of stem cell technologies for cell replacement therapy has progressed rapidly in recent years. Diabetes has long been seen as one of the first applications for stem cell–derived cells because of the loss of only a single cell type—the insulin-producing β-cell. Recent reports have detailed strategies that overcome prior hurdles to generate functional β-like cells from human pluripotent stem cells in vitro, including from human induced pluripotent stem cells (hiPSCs). Even with this accomplishment, addressing immunological barriers to transplantation remains a major challenge for the field. The development of clinically relevant hiPSC derivation methods from patients and demonstration that these cells can be differentiated into β-like cells presents a new opportunity to treat diabetes without immunosuppression or immunoprotective encapsulation or with only targeted protection from autoimmunity. This review focuses on the current status in generating and transplanting autologous β-cells for diabetes cell therapy, highlighting the unique advantages and challenges of this approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and classification of diabetes mellitus
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s081 · Cited by 5,974
Generation of Functional Human Pancreatic β Cells In Vitro
Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., Peterson, Q. P., Greiner, D., & Melton, D. A. (2014) · Cell · doi:10.1016/j.cell.2014.09.040 · Cited by 2,025
Self-citationKroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843 · cited 1×
“Earlier reports demonstrated that, upon transplantation into rodents, a portion of these cells will spontaneously differentiate into b-like cells through an unknown mechanism (17,19), a phenomenon that is the basis for a clinical trial being conducted by ViaCyte, Inc.”
BackgroundReversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells
Rezania, A., Bruin, J. E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O'Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3033 · Cited by 1,575
Type 1 diabetes immunotherapy using polyclonal regulatory T cells
Bluestone, J. A., Buckner, J. H., Fitch, M., Gitelman, S. E., Gupta, S., Hellerstein, M. K., Herold, K. C., Lares, A., Lee, M. R., Li, K., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aad4134 · Cited by 1,033 · cited 1×
“(48) reported persistent C-peptide levels for over 2 years in a phase 1 clinical trial with a small cohort of patients with recent-onset T1D by transplantation of patient-derived T regulatory cells that had been expanded in vitro.”
BackgroundVegas, A. J., Veiseh, O., Gürtler, M., Millman, J. R., Pagliuca, F. W., Bader, A. R., Doloff, J. C., Li, J., Chen, M., Olejnik, K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4030 · Cited by 710 · cited 2×
“This has already been achieved in academic settings (6,7,9) and would require minimal to no scale-up format changes.”
Self-citationHering, B. J., Clarke, W. R., Bridges, N. D., Eggerman, T. L., Alejandro, R., Bellin, M. D., Chaloner, K., Czarniecki, C. W., Goldstein, J. S., Hunsicker, L. G., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1988 · Cited by 645
Controlled induction of human pancreatic progenitors produces functional beta‐like cells in vitro
Russ, H. A., Parent, A. V., Ringler, J. J., Hennings, T. G., Nair, G. G., Shveygert, M., Guo, T., Puri, S., Haataja, L., Cirulli, V., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201591058 · Cited by 591
Rezania, A., Bruin, J. E., Riedel, M. J., Mojibian, M., Asadi, A., Xu, J., Gauvin, R., Narayan, K., Karanu, F., O’Neil, J. J., et al. (2012) · Diabetes · doi:10.2337/db11-1711 · Cited by 582
Guha, P., Morgan, J. W., Mostoslavsky, G., Rodrigues, N. P., & Boyd, A. S. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.01.006 · Cited by 368
Scharp, D. W., & Marchetti, P. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.018 · Cited by 314 · cited 1×
“Micro- and macroencapsulation strategies aim to provide a physical barrier with sufficient permselectivity to allow nutrient and insulin exchange while simultaneously preventing components of the immune system from destroying the transplanted islets (26).”
BackgroundDifferentiated human stem cells resemble fetal, not adult, β cells
Hrvatin, S., O’Donnell, C. W., Deng, F., Millman, J. R., Pagliuca, F. W., DiIorio, P., Rezania, A., Gifford, D. K., & Melton, D. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400709111 · Cited by 302
Self-citationGenetic Background Drives Transcriptional Variation in Human Induced Pluripotent Stem Cells
Rouhani, F., Kumasaka, N., de Brito, M. C., Bradley, A., Vallier, L., & Gaffney, D. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004432 · Cited by 294 · cited 1×
“Patient-to-patient variation in hiPSCs exists because of differences in genetic background, which influences hiPSC gene expression and methylation state (58,59) and likely influences differentiation to b-like cells.”
BackgroundPaull, D., Sevilla, A., Zhou, H., Hahn, A. K., Kim, H., Napolitano, C., Tsankov, A., Shang, L., Krumholz, K., Jagadeesan, P., et al. (2015) · Nature Methods · doi:10.1038/nmeth.3507 · Cited by 263 · cited 1×
“Although costs are currently high for manufacturing each hiPSC line, this cost is likely to continually fall in coming years, particularly with the adoption of more automated processes (55).”
BackgroundKyttälä, A., Moraghebi, R., Valensisi, C., Kettunen, J., Andrus, C., Pasumarthy, K. K., Nakanishi, M., Nishimura, K., Ohtaka, M., Weltner, J., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.12.009 · Cited by 257 · cited 1×
“Patient-to-patient variation in hiPSCs exists because of differences in genetic background, which influences hiPSC gene expression and methylation state (58,59) and likely influences differentiation to b-like cells.”
BackgroundOptimal implantation site for pancreatic islet transplantation
Merani, S., Toso, C., Emamaullee, J., & Shapiro, A. M. J. (2008) · British Journal of Surgery · doi:10.1002/bjs.6391 · Cited by 257
HLA engineering of human pluripotent stem cells
Riolobos, L., Hirata, R. K., Turtle, C. J., Wang, P.-R., Gornalusse, G. G., Zavajlevski, M., Riddell, S. R., & Russell, D. W. (2013) · Molecular Therapy · doi:10.1038/mt.2013.59 · Cited by 253 · cited 1×
“Genetic engineering of a universal cell line is being pioneered by companies like Universal Cells by replacing the class I human leukocyte antigen (HLA) locus with HLA-E or HLA-G to mimic pregnancy-based tolerance of allogeneic tissue, without triggering natural killer cell–based killing, and by deleting transcription…”
BackgroundBaghbaderani, B. A., Tian, X., Neo, B. H., Burkall, A., Dimezzo, T., Sierra, G., Zeng, X., Warren, K., Kovarcik, D. P., Fellner, T., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.08.015 · Cited by 212 · cited 1×
“This approach was used to create cell banks of hiPSCs that express pluripotency markers, maintain normal karyotype, and differentiate into all three germ layers (52).”
MethodAn eye to the future: Researchers debate best path for stem cell-derived therapies
Chakradhar, S. (2016) · Nature Medicine · doi:10.1038/nm0216-116 · Cited by 56 · cited 1×
“However, a second patient has not yet been transplanted for a variety of reasons, including identification of a genomic mutation in the derived autologous hiPSCs (57).”
Background
Cited by
Acquisition of Dynamic Function in Human Stem Cell-Derived β Cells
Velazco-Cruz, L., Song, J., Maxwell, K. G., Goedegebuure, M. M., Augsornworawat, P., Hogrebe, N. J., & Millman, J. R. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.12.012 · Cited by 399
Self-citationTargeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells
Hogrebe, N. J., Augsornworawat, P., Maxwell, K. G., Velazco-Cruz, L., & Millman, J. R. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0430-6 · Cited by 373
Self-citationNext-generation stem cells — ushering in a new era of cell-based therapies
Kimbrel, E. A., & Lanza, R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0064-x · Cited by 275
Generation of insulin-producing pancreatic β cells from multiple human stem cell lines
Hogrebe, N. J., Maxwell, K. G., Augsornworawat, P., & Millman, J. R. (2021) · Nature Protocols · doi:10.1038/s41596-021-00560-y · Cited by 211
Self-citationMaxwell, K. G., Augsornworawat, P., Velazco-Cruz, L., Kim, M. H., Asada, R., Hogrebe, N. J., Morikawa, S., Urano, F., & Millman, J. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax9106 · Cited by 183
Self-citation
Metadata
- Authors
- Millman, J. R., & Pagliuca, F. W.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2017-04-13
- Volume
- 66
- Issue
- 5
- Pages
- 1111-1120
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2608182982
- Cited by
- 99
- References
- 19
- FWCI
- 9.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.